G-HOPE-001
What it tests: Arcotatug tavatecan (IBI343/TAK-921) vs physician’s choice in previously treated advanced gastric or GEJ adenocarcinoma (first interim analysis)
The week in oncology, in your inbox
The OncoAlert Newsletter goes to 10,000+ oncologists and cancer stakeholders: every week, and every day during the major congresses. Free, independent, GDPR-compliant and easy to leave.